In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Small tolerated enalapril doses before ARNI administration predicts adverse events during ARNI up-titration

Session Poster Session 2

Speaker Argyrios Ntalianis

Event : Heart Failure 2019

  • Topic : heart failure
  • Sub-topic : Chronic Heart Failure: Pharmacotherapy
  • Session type : Poster Session

Authors : A Ntalianis (Athens,GR), IP Petropoulous (Athens,GR), I Stamoulopoulos (Athens,GR), E Repasos (Athens,GR), G Maglaras (Athens,GR), A Mareti (Athens,GR), M Kondylis (Athens,GR), N Zografos (Athens,GR), A Koen (Athens,GR), K Tampakis (Athens,GR), A Misegiannidis (Athens,GR), E Venieri (Athens,GR), N Makris (Athens,GR), I Kanakakis (Athens,GR), I Paraskevaidis (Athens,GR)

Authors:
A Ntalianis1 , IP Petropoulous1 , I Stamoulopoulos1 , E Repasos1 , G Maglaras1 , A Mareti1 , M Kondylis1 , N Zografos1 , A Koen1 , K Tampakis1 , A Misegiannidis1 , E Venieri1 , N Makris1 , I Kanakakis1 , I Paraskevaidis1 , 1University of Athens Medical School, Dept of Clinical Therapeutics, Alexandra Hospital - Athens - Greece ,

Citation:

Background/Introduction: The maximum recommended dose (200 mg BID) of sabutipril-valsartan (ARNI) is associated with better prognosis in patients with heart failure and reduced ejection fraction (HFrEF). Theoretically, small tolerated enalapril doses might associate with lower ARNI tolerated doses

Purpose: To investigate the possible association of small tolerated enalapril doses before ARNI with adverse events after ARNI switch.

Methods: Patients with HFrEF (EF£35%), NYHA class II and III at maximum tolerated dose of ß-blocker, enalapril and spironolactone were considered eligible for the study. All patients were switched from enalapril to ARNI which it was progressively up-titrated every week from 50mg BID to 100mg BID and eventually 200mgX2. Enalapril dosage £5 mg BID prior to ARNI was considered as  "low dose" (LD), while a dose> 5 mg / BID was considered as a "high dose" (HD).

Results: A total of 33 patients with a mean age of 59.5 years (84.8% with ischemic myocardiopathy) were prospectively included. 82% of patients were receiving LD of enalapril before ARNI and 18% HD. Overall, 70% of the patients were titrated to the maximum dose of ARNI. Fewer LD patients were up-titrated to the maximum target ARNI dose as compared with the HD group patients (66.6% vs. 83.3%, p=0.01). Only patients in the LD group experienced adverse events during ARNI up-titration (1 patient asymptomatic hypotension, 2 patients symptomatic hypotension and 2 patients hyperkalaemia).

Conclusions: Low tolerated enalapril doses before ARNI administration are associated with a lower probability of ARNI up-titration at the maximum recommend dose and more adverse effects during ARNI administration.

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are